Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IXHL Stock Forecast 2025-2026
$0.22
Current Price
$5.95M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IXHL Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
IXHL Price Momentum
-15.4%
1 Week Change
-64.5%
1 Month Change
-92.1%
1 Year Change
-89.6%
Year-to-Date Change
-93.9%
From 52W High of $3.55
+172.5%
From 52W Low of $0.08
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Incannex Healthcare (IXHL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IXHL and similar high-potential opportunities.
Latest IXHL Stock Price Targets & Analyst Predictions
IXHL has shown a year-to-date change of -89.6% and a 1-year change of -92.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for IXHL. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IXHL Analyst Ratings
0
Buy
0
Hold
0
Sell
IXHL Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.22
Latest IXHL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IXHL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 8, 2022 | Mizuho | Neutral | Maintains | $0.00 | |
| Nov 16, 2022 | Keybanc | Sector Weight | Downgrade | $0.00 | |
| Nov 3, 2022 | Mizuho | Neutral | Downgrade | $0.00 | |
| Nov 3, 2022 | Raymond James | Outperform | Maintains | $0.00 | |
| Nov 3, 2022 | RBC Capital | Outperform | Maintains | $0.00 | |
| Nov 3, 2022 | Barclays | Overweight | Maintains | $0.00 | |
| Nov 3, 2022 | Truist Securities | Hold | Downgrade | $0.00 | |
| Oct 24, 2022 | Keybanc | Overweight | Maintains | $0.00 | |
| Oct 24, 2022 | Truist Securities | Buy | Maintains | $0.00 | |
| Oct 24, 2022 | RBC Capital | Outperform | Maintains | $0.00 | |
| Oct 24, 2022 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
| Oct 21, 2022 | Needham | Hold | Downgrade | $0.00 | |
| Oct 17, 2022 | Mizuho | Buy | Maintains | $0.00 | |
| Oct 11, 2022 | Canaccord Genuity | Buy | Initiates | $0.00 | |
| Sep 23, 2022 | BTIG | Neutral | Initiates | $0.00 | |
| Aug 4, 2022 | Needham | Buy | Maintains | $0.00 | |
| Aug 4, 2022 | Mizuho | Buy | Maintains | $0.00 | |
| Aug 4, 2022 | Raymond James | Outperform | Maintains | $0.00 | |
| Aug 4, 2022 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
| Aug 1, 2022 | RBC Capital | Outperform | Maintains | $0.00 |
Incannex Healthcare Inc. (IXHL) Competitors
The following stocks are similar to Incannex Healthcare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IXHL
Incannex Healthcare
mkt cap
7.04M
Incannex Healthcare Inc. (IXHL) Financial Data
Incannex Healthcare Inc. has a market capitalization of $5.95M with a P/E ratio of -0.2x. The company generates $98,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -33,733.3% and return on equity of -240.0%.
Valuation Metrics
Market Cap
$5.95M
Enterprise Value
$6.79M
P/E Ratio
-0.2x
PEG Ratio
-0.1x
Price/Sales
60.7x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-33,733.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+53.7%
Current Ratio
1.8x
Debt/Equity
424.6x
ROE
-240.0%
ROA
-82.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Incannex Healthcare Inc. (IXHL) Business Model
About Incannex Healthcare Inc.
What They Do
Develops medicinal cannabis and psychedelic therapies.
Business Model
The company focuses on research and commercialization of innovative treatments that combine cannabinoids and psychedelics for various medical conditions. It generates revenue through the development of therapeutic products aimed at addressing issues like anxiety, pain, and sleep disorders, leveraging partnerships with universities and research institutions for validation.
Additional Information
Incannex Healthcare operates within the rapidly growing alternative therapeutics sector, benefiting from global shifts toward legalization and acceptance of medicinal cannabis and psychedelics. The company's efforts not only aim to provide new treatment options but also to shift perceptions around traditional medical therapies.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9
CEO
Mr. Joel Bradley Latham
Country
Australia
IPO Year
2022
Website
www.incannex.comIncannex Healthcare Inc. (IXHL) Latest News & Analysis
Latest News
Quick Summary
The company raised $12.5 million through an At-The-Market (ATM) offering to bolster shareholder position in anticipation of Phase 2 data for IHL-42X.
Why It Matters
The $12.5M raised via ATM signals confidence in upcoming Phase 2 data for IHL-42X, potentially enhancing shareholder value and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
9 days ago
Quick Summary
Incannex Healthcare (Nasdaq: IXHL) reported fiscal Q2 results for the period ending March 31, 2025, highlighting progress in the IHL-42X development program.
Why It Matters
Incannex's fiscal results and progress on the IHL-42X program signal potential growth and innovation, influencing investor sentiment and stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Incannex Healthcare Inc (IXHL) shares rose 876% to 83 cents after completing patient dosing in the Phase 2 portion of its RePOSA trial for the OSA treatment IHL-42X.
Why It Matters
The 876% surge in Incannex Healthcare's shares reflects strong investor confidence following successful trial progress, signaling potential market value and future revenue from IHL-42X.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Patient dosing is finished in the Phase 2 of the Phase 2/3 RePOSA study for IHL-42X, an oral treatment for OSA. Follow-up assessments are expected to conclude by May 17, 2025.
Why It Matters
Completion of patient dosing signals progress in drug development for OSA, potentially impacting future revenues and stock performance based on trial outcomes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Incannex Healthcare Inc. has entered agreements with Series A Warrants holders, allowing a potential reduction of up to 50.4% in common stock shares tied to these warrants.
Why It Matters
Incannex's agreements to reduce shares underlying Series A Warrants can decrease dilution risk, potentially enhancing shareholder value and improving stock price stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Incannex Healthcare has completed Phase 2 patient enrollment for its Phase 2/3 RePOSA study of IHL-42X, aimed at treating Obstructive Sleep Apnea.
Why It Matters
Completion of Phase 2 enrollment in the IHL-42X study signals advancement in drug development, potentially boosting Incannex's valuation and market position if successful.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IXHL Stock
What is Incannex Healthcare Inc.'s (IXHL) stock forecast for 2025?
Analyst forecasts for Incannex Healthcare Inc. (IXHL) are not currently available. The stock is trading at $0.22.
Is IXHL stock a good investment in 2025?
Analyst ratings for IXHL are not currently available. The stock is currently trading at $0.22. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IXHL stock?
Price predictions from Wall Street analysts for IXHL are not currently available. The stock is trading at $0.22.
What is Incannex Healthcare Inc.'s business model?
The company focuses on research and commercialization of innovative treatments that combine cannabinoids and psychedelics for various medical conditions. It generates revenue through the development of therapeutic products aimed at addressing issues like anxiety, pain, and sleep disorders, leveraging partnerships with universities and research institutions for validation.
What is the highest forecasted price for IXHL Incannex Healthcare Inc.?
Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $0.22.
What is the lowest forecasted price for IXHL Incannex Healthcare Inc.?
Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $0.22.
What is the overall IXHL consensus from analysts for Incannex Healthcare Inc.?
Analyst ratings for IXHL are not currently available. The stock is trading at $0.22.
How accurate are IXHL stock price projections?
Stock price projections, including those for Incannex Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 8:28 AM UTC